Recent events
Recent events tied to this brand in public sources.
Back to profile5 entries
2026
Hengrui Pharma and Shifangyun sign strategic cooperation agreement
Hengrui Pharma and Shifangyun signed a strategic cooperation agreement to build an AI-agent ecosystem for pharmaceuticals. Shifangyun will provide AI technology and data-governance capabilities, while Hengrui will provide pharmaceutical research and development, clinical research, and manufacturing resources.
2026
Novo Nordisk to pay up to $2.6 billion to Hengrui for rights to weight-loss pill
Reuters reported that Novo Nordisk is to pay up to $2.6 billion to China's Hengrui Pharma for rights to a weight-loss pill.
2021
Hengrui announces investment and YY-20394 rights agreement with Yingli Pharma
Hengrui Pharma announced a proposed $20 million investment in Yingli Pharma and an agreement granting Hengrui joint development rights and exclusive commercialization rights for YY-20394 in Greater China.
2020
Hengrui responds to media questions about subsidiary employee bribery case and sales expenses
Hengrui Pharmaceutical said a subsidiary employee’s conduct in a bribery case involving a doctor at a Zhejiang hospital seriously violated company rules and exposed management gaps. It said the relevant personnel had left and the subsidiary’s responsible leader had been transferred from the post, and said it would strengthen compliance management of subsidiaries. The company also responded to media questions about sales expenses.
2020
Hengrui Medicine releases 2019 annual results
Hengrui Medicine released its 2019 results on March 22, reporting revenue of 23.289 billion yuan and net profit attributable to shareholders of 5.328 billion yuan.